FDA approves first TPO agonist for chronic liver disease

FDA approves first TPO agonist for chronic liver disease

Source: 
Biopharma Dive
snippet: 

Following a priority review, the Food and Drug Administration has approved Dova Pharmaceuticals' Doptelet for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.